Thermo Fisher Scientific’s Pharma Services business has been awarded five multi‐year contracts collectively valued at over $450 million to relocate biologics and small‐molecule production from Europe and Asia into U.S. facilities, CEO Marc Casper announced. The agreements span fill-finish, analytical testing and cold‐chain logistics for three top 10 global biopharma companies. By leveraging its recently expanded 200,000-square-foot fill-finish facility in Indianapolis and a new $120 million analytical lab in Boston, Thermo Fisher expects to increase domestic cGMP capacity by 30% by year-end 2027. These additions are part of the company’s $1.3 billion capital expenditure plan for pharma manufacturing over the next three years, designed to capture reshoring demand driven by regulatory incentives and customer supply-chain risk mitigation strategies.

Thermo Fisher has entered a strategic collaboration with NVIDIA to integrate BioNeMo AI models and DGX AI compute into its instrument portfolio, creating what the companies describe as a next-generation autonomous lab platform. The partnership will deploy 150 NVIDIA DGX Spark desktop supercomputers in Thermo Fisher’s major research sites, enabling real-time data analysis for high-throughput screening and protocol optimization. In pilot trials at Thermo Fisher’s Waltham, MA research campus, the joint system processed 20% more samples per week and reduced assay turnaround times by 25%. Executive Vice President Gianluca Pettitti said the goal is to roll out unified edge-to-cloud workflows in 50 customer labs by mid-2026, targeting a 40% reduction in manual intervention for routine experiments.

Michel Lagarde, Thermo Fisher’s Chief Operating Officer since 2021 and architect of the company’s global supply-chain modernization program, will leave the organization in March to pursue an external opportunity, the company confirmed. Under Lagarde’s leadership, Thermo Fisher achieved a 15% reduction in manufacturing cycle times and integrated 12 newly acquired sites into its operations network, contributing to a 9% margin expansion in FY 2024. The board has initiated a global search for a successor, with interim responsibilities assumed by EVP of Lab Products & Services, Mark Stevenson. Management reaffirmed its full-year guidance for adjusted operating margin of 25% and free cash flow north of $5 billion despite the transition at the top of operations.